Clear Harbor Asset Management LLC grew its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 39,923 shares of the company’s stock after buying an additional 92 shares during the period. Johnson & Johnson makes up 0.9% of Clear Harbor Asset Management LLC’s portfolio, making the stock its 24th largest position. Clear Harbor Asset Management LLC’s holdings in Johnson & Johnson were worth $7,052,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the company. Lincoln Capital Corp lifted its stake in Johnson & Johnson by 15.9% in the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after acquiring an additional 183 shares in the last quarter. Ieq Capital LLC lifted its position in shares of Johnson & Johnson by 5.1% in the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after purchasing an additional 6,154 shares in the last quarter. RFG Advisory LLC boosted its holdings in Johnson & Johnson by 2.7% during the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after purchasing an additional 594 shares during the last quarter. Willis Investment Counsel increased its stake in Johnson & Johnson by 0.4% in the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after buying an additional 1,358 shares during the last quarter. Finally, FDx Advisors Inc. lifted its position in Johnson & Johnson by 0.3% during the 3rd quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock worth $8,237,000 after buying an additional 153 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the company. SVB Leerink lowered their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Citigroup upped their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, Piper Sandler decreased their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.67.
Insiders Place Their Bets
Johnson & Johnson Trading Up 1.0 %
Shares of JNJ stock opened at $155.00 on Monday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $186.69. The company has a market capitalization of $403.66 billion, a PE ratio of 23.00, a price-to-earnings-growth ratio of 2.64 and a beta of 0.54. The firm has a 50 day moving average price of $158.02 and a two-hundred day moving average price of $167.18. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period last year, the firm posted $2.13 EPS. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is 67.06%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
